APR Applied Pharma Research S.A. And Angelini Enter Into An Exclusive Licensing Agreement For APR’s Innovative Product In Acute And Chronic Wound Management

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROME & BALERNA, Switzerland--(BUSINESS WIRE)--Angelini and APR announced today that they have entered into a strategic partnership to support and promote a novel and innovative product developed by APR for the management of a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers. The product, characterized by acidic and super-oxidizing features in an easy-to-use formulation, acts by improving the functional conditions of the physiological wound healing process, providing the healthcare professional and the patient with an effective, convenient and patient-friendly treatment option.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC